COMMERCIALIZATION

COMMERCIALIZATION

Commercialization is a strategic priority for LSI. Our strong track record in translational research includes both spinning off new companies and establishing collaborations with industrial partners.


Knowledge Translation:

lsi_knowledgetranslation_v1

Over 20 spinoffs, 250 granted patents, 80 technologies and 60 commercial partners.

lsi_impactingdrugs_v1

3 approved drugs and 10 in trials.


Spinoffs and Technology

LSI researchers have founded over 20 companies, among them: Tekmira, a publicly traded company with a diverse pipeline of drug candidates for diseases such as cancer and viral infections; TerraGen Discovery that developed technologies to facilitate drug discovery from environmental sources, and was acquired by Cubist Pharmaceuticals for $29M; and EnGene, that has raised over $20M in venture funding to build an innovative mucosal immunotherapy platform for treatment of several prevalent, chronic diseases including IBD and diabetes.

Read More


Industrial Collaboration

UBC’s world class expertise in Life Sciences, cutting edge equipment, strong clinical integration, flexible IP policies and low overhead create an attractive value proposition and foster numerous industrial collaborations. LSI researchers are working with both local and global industrial partners and over 80 of our technologies have been successfully commercialized.

Read More


Resources for Entrepreneurs

Small businesses in British Columbia benefit from numerous federal and provincial programs providing support, education and undiluted funding to start-ups in innovation sectors. LSI is partnering with numerous organization within UBC, such as entrepreneurship@UBC, CDRD and UILO to further facilitate spinning off a new Life Sciences company, giving our entrepreneurs access to advanced facilities, workshops, mentors, seed funding, incubator space and more.

Read More